// App-Quantinova.ai

5048.0 : Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.

Researchers

Presenter

  • Catherine Curran

Principal Investigators

  • Gregory Russell Pond

  • Vera Kazakova

  • Petros Grivas

  • Leonidas Nikolaos Diamantopoulos

  • Ajjai Shivaram Alva

  • Christopher Su

  • Rohit K. Jain

  • Ankita Tandon

  • Jingsong Zhang

  • Andrea Necchi

  • Laura Marandino

  • Jaime R. Merchan

  • Trisha M. Plastini

  • Guru Sonpavde

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • McMaster University, Department of Surgery, Hamilton, ON, Canada

  • Steward St Elizabeths Medical Center, Boston, MA

  • University of Washington, Seattle, WA

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • University of Michigan Medical School, Ann Arbor, MI

  • Moffitt Cancer Center, Tampa, FL

  • University of South Florida, Tampa, FL

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy

  • Department of Oncology, University of Torino, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

  • University of Miami, Miami, FL

  • University of Pennsylvania Medical Center, Philadelphia, PA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Enfortumab vedotin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved